Pfizer BioNTech Covid-19 Lipid Nanoparticle Components and Vaccine Administration

In 2020-2021, the lipid nanoparticles (LNPs) emphasized as the forefront of science and technology when Pfizer/BioNTech and Moderna vaccines used those formulations for delivering messenger RNA (mRNA) and protected the mRNA molecules from degradation. Highly encapsulated LNP-mRNA led to effectiveness with intracellular delivery and endosomal escape in the nucleoside-modified mRNA-LNP. Specifically the lipid nanoparticle in Pfizer - BioNTech vaccines included the following formulation components:

  1. Potassium chloride
  2. Monobasic potassium phosphate
  3. Sodium chloride
  4. Dibasic sodium phosphate dihydrate
  5. Sucrose
  6. Lipid 1: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2- hexyldecanoate),
  7. Lipid 2: 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 1,2-distearoyl-snglycero-3-phosphocholine, and cholesterol)

The Pfizer-BioNTech COVID-19 Vaccine is stored in a freezing condition to protect the mRNA stability, and it is supplied as a frozen [between -80°C to -60°C (- 112°F to -76°F)] in five-dose vials. At the point of administration, the vaccine would be thawed and diluted in 1.8mL of sterile 0.9% Sodium Chloride Injection. After this, the vial will contain five doses that could be administrated to applicants. The vaccines have to be utilized within 6 hours of dilution and must be stored at 2-25°C or (35°F to 77°F).  


Vaccines, F.D.A., Related Biological Products Advisory Committee Meeting December 10, 2020. FDA Briefing Document. Pfizer-BioNTech COVID-19 Vaccine.


Leave a comment

Please note, comments must be approved before they are published